News

Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer. In addition, he highlights the latest approvals of checkpoint inhibitors in this patient population.

Wells A. Messersmith, MD, reviews key updates to the NCCN guidelines for the treatment of colorectal cancer.

According to results from the ongoing phase I/II GARNET trial, dostarlimab induced an overall response rate of nearly 30% in patients with recurrent or advanced endometrial cancer. Results presented at the 2019 SGO Annual Meeting also demonstrated durable responses in both patients with microsatellite instability-high and microsatellite stable tumors.

The establishment of a high-risk cancer screening and genetic counseling service in a community setting may be an arduous undertaking but, as demonstrated in a case study presented during the Association of Community Cancer Centers 45th Annual Meeting & Cancer Center Business Center Summit held in Washington, DC, it could help to reduce the chance of patients developing a hereditary cancer.

David Cibula, MD, highlights the phase II data on DCVAC/OvCA in combination with chemotherapy for patients with relapsed, platinum-sensitive ovarian cancer, and how it could impact future treatment approaches for this population.

Be careful with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma, the FDA has warned in an alert to healthcare professionals and clinical investigators.

The combination of FOLFOXIRI plus molecular targeted therapies, including bevacizumab, was effective as a first-line treatment in metastatic colorectal cancer, according to findings from a retrospective study recently published in <em>Oncotarget.</em>

Three next-generation physician practice management companies&mdash;US Oncology Network, American Oncology Network, and OneOncology&mdash;provided an overview of their business models to distinguish themselves from competitors at a breakout session during the Association of Community Cancer Centers 45th Annual Meeting &amp; Cancer Center Business Center Summit held in Washington, DC.

During a <em>Targeted Oncology </em>case-based peer perspectives program, Elias Jabbour, MD, discussed his clinical considerations for the management of chronic myeloid leukemia in chronic phase.&nbsp;Jabbour explained his treatment decisions during the live event based on a case scenario of a patient with CML-CP.

The first patient has been dosed in a phase II study investigating the safety and tolerability of the novel agent LiPlaCis for the treatment of advanced or refractory prostate cancer.

The efficacy of osimertinib does not significantly vary according to the body size variables of patients with T790M-positive non&ndash;small cell lung cancer who progress on prior EGFR tyrosine kinase inhibitors, according to findings from a new study published in <em>Thoracic Cancer</em>.<br /> &nbsp;

Carla Casulo, MD,&nbsp;discusses challenges in the management of patients with relapsed/refractory follicular lymphoma and progress being made toward predicting early relapse in these patients.

The phase III JAVELIN Ovarian PARP 100 study has been discontinued,&nbsp;according to Merck KGaA and Pfizer, the companies that collaborated on the trial.^&nbsp;The ongoing trial was investigating the efficacy and safety&nbsp;of avelumab in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib in patients with locally advanced or metastatic ovarian cancer.

Sarah Rutherford, MD, discusses&nbsp;a pilot study at Weill Cornell Medicine investigating ribavirin as a treatment for patients with follicular lymphoma.

A partial clinical hold has been placed on&nbsp;all clinical trials examining venetoclax in multiple myeloma,&nbsp;according to AbbVie, co-developer of the BCL-2 inhibitor with Genentech. This hold, placed by the FDA,&nbsp;halts enrollment of new patients on the studies.

The clinical practice guidelines for the treatment of patients with colorectal cancer have been updated by NCCN to include the combination of&nbsp;encorafenib plus binimetinib in addition to EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with <em>BRAF</em> V600E&ndash;mutant metastatic CRC, after 1 or 2 prior therapies for metastatic disease.

The FDA has approved the combination of&nbsp;atezolizumab plus carboplatin and etoposide&nbsp;as a first-line treatment for patients with extensive-stage small cell lung cancer.

The biologics license application for&nbsp;eflapegrastim was voluntarily withdrawn by Spectrum Pharmaceuticals as the company requires more time to complete additional manufacturing-related information requested by the FDA.

Ofatumumab was both active and well-tolerated at 2 different dose levels in treatment-na&iuml;ve patients with advanced follicular lymphoma who had low tumor burden, according to findings from a phase II, multicenter study recently published in the <em>British Journal of Haematology</em>.

Ahead of the 50th Annual SGO Meeting, Shannon Westin, MD discussed the key takeaways from a case chat and highlighted some data she is looking forward to at the meeting for patients with recurrent ovarian cancer. She also highlighted other data that will play an important part in this treatment landscape and for patients with recurrent cervical cancer.

Based on 2 case scenarios, H. Jack West, MD, discusses treatment options and the data that support these options for the management of squamous and nonsquamous non&ndash;small cell lung cancer.

Following a recommendation from the&nbsp;Oncologic Drugs Advisory Committee against the accelerated approval of&nbsp;selinexor for the treatment of patients with penta-refractory multiple myeloma, the FDA has added&nbsp;3 months to the review period for the new drug application,&nbsp;making the new action date July 6, 2019.

The treatment paradigm for&nbsp;HER2-positive breast cancer may be reshaped over the next several years, as head-to-head studies comparing new agents to the current standard of care begin to yield results,&nbsp;said Sara A. Hurvitz, MD.

Diagnosis, risk stratification, and the management of patients with polycythemia vera and myelofibrosis have all been significantly improved by the inclusion of a greater understanding of the clinical and molecular characteristics of these 2 different myeloproliferative neoplasms, according to Abdulraheem Yacoub, MD.

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Kartik Konduri, MD, recently discussed the treatment considerations and decisions he makes when treating patients with non&ndash;small cell lung cancer.

Paul J. Shaughnessy, MD,&nbsp;discusses updates in stem cell mobilization and transplant for DLBCL, including the potential for CAR T-cell therapy to supplant autologous stem cell transplant.

The need for new therapies to treat&nbsp;metastatic triple-negative breast cancer is pressing, and the development of&nbsp;antibody-drug conjugates represents a promising new strategy for these patients,&nbsp;according to Aditya Bardia, MD, MPH.

Robert L. Ferris, MD, PhD, Co-Physician Editor in Chief, <em>Targeted Therapies in Oncology</em>,<em>&nbsp;</em>discusses<em>&nbsp;</em>the<em>&nbsp;</em>evolving<em>&nbsp;</em>role of immunotherapy in melanoma and non&ndash;small cell lung cancer, where by it is now the dominant therapeutic approach in these diseases in progressively earlier lines of therapy.

A rolling submission has been completed to the FDA for the potential approval of the combination of daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone (DRd)&nbsp;for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Nab-paclitaxel plus gemcitabine in the adjuvant setting did not improve disease-free survival in patients with pancreatic cancer compared to gemcitabine alone, according to topline results from the phase III APACT trial that have been confirmed by independent radiological review.